[{"id":"463587d3-e808-4685-9d40-3926117c11c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06654050","created_at":"2025-02-25T12:31:09.116Z","updated_at":"2025-02-25T12:31:09.116Z","phase":"Phase 2","brief_title":"Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma","source_id_and_acronym":"NCT06654050","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":"","alterations":" ","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e alrizomadlin (APG-115)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 02/27/2025","start_date":" 02/27/2025","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-02-24"},{"id":"39739443-27b5-47de-9366-d6dcb750b600","acronym":"SGNBB228-001","url":"https://clinicaltrials.gov/study/NCT05571839","created_at":"2022-10-07T13:59:56.834Z","updated_at":"2025-02-25T14:09:10.779Z","phase":"Phase 1","brief_title":"A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors","source_id_and_acronym":"NCT05571839 - SGNBB228-001","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PF-08046049"],"overall_status":"Recruiting","enrollment":" Enrollment 275","initiation":"Initiation: 01/03/2023","start_date":" 01/03/2023","primary_txt":" Primary completion: 04/19/2027","primary_completion_date":" 04/19/2027","study_txt":" Completion: 04/18/2028","study_completion_date":" 04/18/2028","last_update_posted":"2025-02-19"},{"id":"03ad2ae1-62eb-4ee9-9973-fa23d5f2634d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05904496","created_at":"2023-06-15T17:08:23.801Z","updated_at":"2025-02-25T14:18:02.487Z","phase":"Phase 1","brief_title":"A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05904496","lead_sponsor":"BeiGene","biomarkers":" TMB • MSI","pipe":" | ","alterations":" TMB-H • MSI-H/dMMR","tags":["TMB • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H • MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • BGB-30813"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 07/19/2023","start_date":" 07/19/2023","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-17"},{"id":"2b60e541-1e3c-4090-9044-9dd28f2e4baf","acronym":"A092001","url":"https://clinicaltrials.gov/study/NCT05001880","created_at":"2023-11-29T23:15:50.240Z","updated_at":"2025-02-25T14:16:16.072Z","phase":"Phase 2","brief_title":"Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma","source_id_and_acronym":"NCT05001880 - A092001","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" MSLN","pipe":"","alterations":" ","tags":["MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Tecentriq (atezolizumab) • carboplatin • pemetrexed • Aybintio (bevacizumab biosimilar) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Pemfexy (pemetrexed)"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 03/22/2022","start_date":" 03/22/2022","primary_txt":" Primary completion: 08/20/2025","primary_completion_date":" 08/20/2025","study_txt":" Completion: 08/20/2025","study_completion_date":" 08/20/2025","last_update_posted":"2025-02-17"},{"id":"d4485f54-359c-4ee3-8554-f4f3c66c58bb","acronym":"TNG462-C101","url":"https://clinicaltrials.gov/study/NCT05732831","created_at":"2023-02-17T15:00:50.938Z","updated_at":"2025-02-25T14:41:52.620Z","phase":"Phase 1/2","brief_title":"Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors","source_id_and_acronym":"NCT05732831 - TNG462-C101","lead_sponsor":"Tango Therapeutics, Inc.","biomarkers":" MTAP","pipe":" | ","alterations":" MTAP deletion","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MTAP deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • vopimetostat (TNG462)"],"overall_status":"Recruiting","enrollment":" Enrollment 225","initiation":"Initiation: 05/26/2023","start_date":" 05/26/2023","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-14"},{"id":"0e743df4-4d78-48c0-81d7-be2811a46a8b","acronym":"","url":"https://clinicaltrials.gov/study/NCT04431024","created_at":"2021-01-18T21:20:26.688Z","updated_at":"2025-02-25T15:11:35.608Z","phase":"","brief_title":"Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome","source_id_and_acronym":"NCT04431024","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 03/30/2021","start_date":" 03/30/2021","primary_txt":" Primary completion: 06/30/2038","primary_completion_date":" 06/30/2038","study_txt":" Completion: 06/30/2038","study_completion_date":" 06/30/2038","last_update_posted":"2025-02-13"},{"id":"14db2cea-3400-48ac-8ad3-0b56fccbb5a9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03007030","created_at":"2021-01-18T14:47:28.350Z","updated_at":"2025-02-25T15:42:55.122Z","phase":"Phase 2","brief_title":"Brentuximab Vedotin in Treating Patients With CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery","source_id_and_acronym":"NCT03007030","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" TNFRSF8","pipe":" | ","alterations":" TNFRSF8 positive • TNFRSF8 expression","tags":["TNFRSF8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TNFRSF8 positive • TNFRSF8 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Adcetris (brentuximab vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 55","initiation":"Initiation: 04/05/2017","start_date":" 04/05/2017","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2025-02-10"},{"id":"611fb533-b8fd-4219-b354-66257bca25a5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04491942","created_at":"2021-01-18T21:34:47.482Z","updated_at":"2025-02-25T15:26:28.507Z","phase":"Phase 1","brief_title":"Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer","source_id_and_acronym":"NCT04491942","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • elimusertib (BAY 1895344) • liposomal gemcitabine (FF-10832)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2025-02-10"},{"id":"d0aa4f16-7694-44b7-8f9e-f75259b43f62","acronym":"","url":"https://clinicaltrials.gov/study/NCT05544929","created_at":"2022-09-19T14:56:40.664Z","updated_at":"2025-02-25T16:39:18.617Z","phase":"Phase 1","brief_title":"A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers","source_id_and_acronym":"NCT05544929","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Tevimbra (tislelizumab-jsgr) • KFA115"],"overall_status":"Recruiting","enrollment":" Enrollment 180","initiation":"Initiation: 10/26/2022","start_date":" 10/26/2022","primary_txt":" Primary completion: 02/20/2026","primary_completion_date":" 02/20/2026","study_txt":" Completion: 02/20/2026","study_completion_date":" 02/20/2026","last_update_posted":"2025-02-06"},{"id":"b2f66c0e-6c9b-4463-9368-140116887239","acronym":"ACROPOLI","url":"https://clinicaltrials.gov/study/NCT04802876","created_at":"2021-03-17T15:57:42.481Z","updated_at":"2025-02-25T15:44:25.480Z","phase":"Phase 2","brief_title":"Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors","source_id_and_acronym":"NCT04802876 - ACROPOLI","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" PD-1","pipe":" | ","alterations":" PD-1 expression","tags":["PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tevimbra (tislelizumab-jsgr) • spartalizumab (PDR001)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 184","initiation":"Initiation: 04/12/2021","start_date":" 04/12/2021","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2025-02-04"},{"id":"42d2a0f4-bf25-41be-9b41-ecad4c959f5d","acronym":"CK-301-101","url":"https://clinicaltrials.gov/study/NCT03212404","created_at":"2021-01-18T15:50:41.447Z","updated_at":"2025-02-25T16:59:32.024Z","phase":"Phase 1","brief_title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","source_id_and_acronym":"NCT03212404 - CK-301-101","lead_sponsor":"Checkpoint Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unloxcyt (cosibelimab-ipdl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"a3420852-8b9f-44e2-8ed6-3f7ccc1cb129","acronym":"BASECAMP-1","url":"https://clinicaltrials.gov/study/NCT04981119","created_at":"2021-07-28T19:52:39.410Z","updated_at":"2025-02-25T17:37:14.992Z","phase":"","brief_title":"Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing","source_id_and_acronym":"NCT04981119 - BASECAMP-1","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 10/29/2021","start_date":" 10/29/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-01-29"},{"id":"5037edde-68fc-4ba2-be19-0dd9cdd215d1","acronym":"INFINITE","url":"https://clinicaltrials.gov/study/NCT03710876","created_at":"2025-02-26T07:43:54.912Z","updated_at":"2025-02-26T07:43:54.912Z","phase":"Phase 3","brief_title":"Efficacy \u0026 Safety of RAd-IFN Administered with Celecoxib \u0026 Gemcitabine in Patients with Malignant Pleural Mesothelioma","source_id_and_acronym":"NCT03710876 - INFINITE","lead_sponsor":"Ferring Ventures Limited","biomarkers":" MSLN • EFEMP1","pipe":"","alterations":" ","tags":["MSLN • EFEMP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • Adstiladrin (nadofaragene firadenovec-vncg) • celecoxib oral"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 01/21/2019","start_date":" 01/21/2019","primary_txt":" Primary completion: 03/29/2024","primary_completion_date":" 03/29/2024","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2024-11-08"},{"id":"ea9d9a0b-27c4-491d-a445-ee1deb626c7c","acronym":"DREAM3R","url":"https://clinicaltrials.gov/study/NCT04334759","created_at":"2021-01-18T20:59:16.502Z","updated_at":"2025-02-25T14:58:58.769Z","phase":"Phase 3","brief_title":"DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma","source_id_and_acronym":"NCT04334759 - DREAM3R","lead_sponsor":"PrECOG, LLC.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • pemetrexed"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 214","initiation":"Initiation: 02/18/2021","start_date":" 02/18/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 02/01/2026","study_completion_date":" 02/01/2026","last_update_posted":"2024-11-07"},{"id":"7ce398ac-e594-403c-828e-b3f6d6572732","acronym":"PEMMELA","url":"https://clinicaltrials.gov/study/NCT04287829","created_at":"2021-01-18T20:48:44.381Z","updated_at":"2025-02-25T16:10:03.930Z","phase":"Phase 2","brief_title":"Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients","source_id_and_acronym":"NCT04287829 - PEMMELA","lead_sponsor":"The Netherlands Cancer Institute","biomarkers":" TMB • CTLA4","pipe":"","alterations":" ","tags":["TMB • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Lenvima (lenvatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 58","initiation":"Initiation: 03/01/2021","start_date":" 03/01/2021","primary_txt":" Primary completion: 12/05/2024","primary_completion_date":" 12/05/2024","study_txt":" Completion: 03/05/2026","study_completion_date":" 03/05/2026","last_update_posted":"2024-11-05"},{"id":"14a6bde6-48dd-43fd-b20a-941240b312eb","acronym":"","url":"https://clinicaltrials.gov/study/NCT04515836","created_at":"2021-01-18T21:38:23.683Z","updated_at":"2025-02-25T14:59:18.583Z","phase":"Phase 2","brief_title":"Olaparib in Patients With HRD Malignant Mesothelioma","source_id_and_acronym":"NCT04515836","lead_sponsor":"University of Chicago","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • cisplatin"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 02/19/2021","start_date":" 02/19/2021","primary_txt":" Primary completion: 04/15/2025","primary_completion_date":" 04/15/2025","study_txt":" Completion: 04/15/2025","study_completion_date":" 04/15/2025","last_update_posted":"2024-10-23"},{"id":"7d21338e-ff73-41cf-853f-9516a337a92e","acronym":"FIH","url":"https://clinicaltrials.gov/study/NCT04104776","created_at":"2021-08-13T14:52:51.135Z","updated_at":"2025-02-25T15:43:41.485Z","phase":"Phase 1/2","brief_title":"A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas","source_id_and_acronym":"NCT04104776 - FIH","lead_sponsor":"Constellation Pharmaceuticals","biomarkers":" MSI • ARID1A • BAP1","pipe":" | ","alterations":" MSI-H/dMMR • ARID1A mutation","tags":["MSI • ARID1A • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • ARID1A mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • tulmimetostat (DZR123)"],"overall_status":"Recruiting","enrollment":" Enrollment 210","initiation":"Initiation: 09/18/2019","start_date":" 09/18/2019","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-08-02"},{"id":"06560225-2b42-48b3-bbbc-b9ae314d8a0d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04040231","created_at":"2021-02-01T11:53:19.132Z","updated_at":"2024-07-02T16:34:26.088Z","phase":"Phase 1","brief_title":"Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma","source_id_and_acronym":"NCT04040231","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" WT1","pipe":"","alterations":" ","tags":["WT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Zeltherva (galinpepimut-S) • Leukine (sargramostim)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/24/2019","start_date":" 07/24/2019","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-06-14"},{"id":"566dbbb6-eabe-4dfb-be9c-7161bcda7964","acronym":"","url":"https://clinicaltrials.gov/study/NCT05960773","created_at":"2023-07-27T18:08:58.951Z","updated_at":"2024-07-02T16:34:37.145Z","phase":"Phase 2","brief_title":"Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma","source_id_and_acronym":"NCT05960773","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BAP1","pipe":" | ","alterations":" BAP1 mutation","tags":["BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BAP1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/31/2024","start_date":" 01/31/2024","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-07"},{"id":"78b229da-43da-49fb-9bb1-8557ce0bcba9","acronym":"","url":"https://clinicaltrials.gov/study/NCT03830229","created_at":"2021-01-18T18:54:52.823Z","updated_at":"2024-07-02T16:34:38.028Z","phase":"","brief_title":"Long Term Follow-up of Mesothelioma Patients and Their Family Members With Germline Mutations in BAP1 and Other Genes","source_id_and_acronym":"NCT03830229","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" TP53 • BAP1","pipe":" | ","alterations":" TP53 mutation • BAP1 mutation","tags":["TP53 • BAP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • BAP1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 03/13/2019","start_date":" 03/13/2019","primary_txt":" Primary completion: 07/06/2026","primary_completion_date":" 07/06/2026","study_txt":" Completion: 07/05/2027","study_completion_date":" 07/05/2027","last_update_posted":"2024-06-05"},{"id":"19720944-036d-444d-865d-588a5ff231f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04836429","created_at":"2021-04-08T13:52:42.896Z","updated_at":"2024-07-02T16:34:59.219Z","phase":"Phase 1","brief_title":"Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease","source_id_and_acronym":"NCT04836429","lead_sponsor":"Roswell Park Cancer Institute","biomarkers":" PD-L1","pipe":" | ","alterations":" PD-L1 expression","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Photofrin (porfimer sodium)"],"overall_status":"Suspended","enrollment":" Enrollment 16","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 03/17/2025","primary_completion_date":" 03/17/2025","study_txt":" Completion: 03/17/2025","study_completion_date":" 03/17/2025","last_update_posted":"2024-06-04"},{"id":"3459cfe0-8df3-41ce-b99a-ba11d3ea3232","acronym":"EVEREST-2","url":"https://clinicaltrials.gov/study/NCT06051695","created_at":"2023-09-25T14:10:18.366Z","updated_at":"2024-07-02T16:34:59.359Z","phase":"Phase 1/2","brief_title":"A Study to Evaluate the Safety and Efficacy of A2B694, a Logic-gated CAR T, in Subjects With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression","source_id_and_acronym":"NCT06051695 - EVEREST-2","lead_sponsor":"A2 Biotherapeutics Inc.","biomarkers":" HLA-A • MSLN","pipe":" | ","alterations":" MSLN expression • HLA-A*02","tags":["HLA-A • MSLN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • HLA-A*02"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 04/03/2024","start_date":" 04/03/2024","primary_txt":" Primary completion: 06/01/2028","primary_completion_date":" 06/01/2028","study_txt":" Completion: 06/01/2029","study_completion_date":" 06/01/2029","last_update_posted":"2024-06-04"},{"id":"84e4e85b-e9f7-4b35-bc39-067c74a8a32d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05337735","created_at":"2022-04-20T15:53:51.350Z","updated_at":"2024-07-02T16:34:58.974Z","phase":"Phase 2","brief_title":"A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers","source_id_and_acronym":"NCT05337735","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e vudalimab (XmAb717)"],"overall_status":"Suspended","enrollment":" Enrollment 140","initiation":"Initiation: 08/05/2022","start_date":" 08/05/2022","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-06-04"},{"id":"f8a566d4-1220-4795-a41e-999d20763d92","acronym":"","url":"https://clinicaltrials.gov/study/NCT05245500","created_at":"2022-02-18T14:52:54.785Z","updated_at":"2024-07-02T16:34:59.606Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion","source_id_and_acronym":"NCT05245500","lead_sponsor":"Mirati Therapeutics Inc.","biomarkers":" MTAP","pipe":"","alterations":" ","tags":["MTAP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e navlimetostat (BMS‐986504)"],"overall_status":"Recruiting","enrollment":" Enrollment 370","initiation":"Initiation: 06/02/2022","start_date":" 06/02/2022","primary_txt":" Primary completion: 04/30/2026","primary_completion_date":" 04/30/2026","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-06-03"}]